SCHEMBL29630264

SCHEMBL29630264

Cc1cc2oc(C)c(C(=O)O)c2cc1OCc1cccnc1C(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC26A4 O43511 7/20 0.51
KMT2A Q03164 5/20 0.46
MEN1 O00255 4/20 0.46
POLB P06746 2/20 0.42
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTT P42858 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
F11 P03951 2/20 0.39
BLM P54132 1/20 0.39
ATM Q13315 1/20 0.39
CD38 P28907 1/20 0.38
FFAR1 O14842 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
PPARG P37231 1/20 0.37
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24485049 1.00 SLC26A4 (0.51) SLC26A4KMT2AMEN1POLBLMNA
SCHEMBL24484512 0.91 SLC26A4 (0.48) SLC26A4KMT2AMEN1POLBLMNA
SCHEMBL29630147 0.91 SLC26A4 (0.48) SLC26A4KMT2AMEN1POLBLMNA
SCHEMBL29630119 0.90 SLC26A4 (0.45) SLC26A4KMT2AMEN1POLBLMNA
SCHEMBL24485758 0.90 SLC26A4 (0.45) SLC26A4KMT2AMEN1POLBLMNA
SCHEMBL24485054 0.90 PTGS2 (0.48) LMNATDP1L3MBTL1HTTF11
SCHEMBL24485031 0.85 SLC26A4 (0.69) SLC26A4KMT2AMEN1POLBLMNA
SCHEMBL30719905 0.84 SLC26A4 (0.48) SLC26A4KMT2AMEN1POLBLMNA
SCHEMBL26699024 0.84 SLC26A4 (0.48) SLC26A4KMT2AMEN1POLBLMNA
SCHEMBL24485423 0.82 SLC26A4 (0.43) SLC26A4KMT2AMEN1POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-01-28 US disclosed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 SLC26A4 628/4885KMT2A 3314/4885MEN1 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.